Targeting Cutaneous Cannabinoid Signaling in Inflammation: a "High"-way to Heal? by Oláh, Attila & Bíró, Tamás
EBioMedicine 16 (2017) 3–5
Contents lists available at ScienceDirect
EBioMedicine
j ourna l homepage: www.eb iomed ic ine.comIn FocusTargeting Cutaneous Cannabinoid Signaling in Inflammation - A
“High”-way to Heal?Attila Oláh a,⁎, Tamás Bíró a,b
a Department of Physiology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary
b Department of Immunology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary⁎ Corresponding author at: Department of Physiology, Fa
Debrecen, Nagyerdei krt. 98., Debrecen H-4032, Hungary.
E-mail address: olah.attila@med.unideb.hu (A. Oláh).
http://dx.doi.org/10.1016/j.ebiom.2017.01.003
2352-3964/© 2017 The Authors. Published by Elsevier B.Va r t i c l e i n f oArticle history:
Received 28 November 2016
Received in revised form 29 December 2016
Accepted 4 January 2017
Available online 7 January 2017
(Karsak et al., 2007). Moreover, AEA was recently shown to suppress
production and release of key Th1- and Th17-polarizing cytokines (IL-
12 and IL-23) via CB1-mediated inhibition of mammalian target of
rapamycin (mTOR) in human keratinocytes (Chiurchiù et al., 2016).
Collectively, these findings (together with many other recently pub-
lished data) implied keratinocytes to be “non-classical” immune com-
petent cells, playing a central role in initiation and regulation ofThe endocannabinoid system (ECS) is a recently emerging complex
regulator of multiple physiological processes. It comprises several en-
dogenous ligands (e.g. N-arachidonoylethanolamine, a.k.a. anandamide
[AEA], 2-arachidonoylglycerol [2-AG], palmitoylethanolamide [PEA],
etc.), a number of endocannabinoid (eCB)-responsive receptors (e.g.
CB1 and CB2, etc.), as well as enzymes and transporters involved in the
synthesis and degradation of the eCBs (extensively reviewed in
Maccarrone et al., 2015; Ligresti et al., 2016).
Among many other tissues and organs, various members of the ECS
were shown to be expressed in the skin as well. Indeed, AEA, 2-AG, CB1
and CB2 together with the major eCB-metabolizing enzymes (e.g. fatty
acid amide hydrolase [FAAH], which cleaves AEA to ethanolamine and
pro-inflammatory arachidonic acid) were found in various cutaneous
cell types. Importantly, the eCB-tone and cannabinoid signaling in gen-
eral appear to play a key role in regulating several fundamental aspects
of cutaneous homeostasis, including proliferation and differentiation of
epidermal keratinocytes, hair growth, sebaceous lipid production,mela-
nogenesis, fibroblast activity, etc. (reviewed in Bíró et al., 2009;
Maccarrone et al., 2015). Moreover, appropriate eCB-signaling through
CB1 and CB2 receptors was found to be crucially important in keeping
cutaneous inflammatory processes under control (Karsak et al., 2007).
Indeed, by using CB1 and CB2 double KO (DKO) as well as wild-type
(WT)mice, Karsak et al. demonstrated that DKO animals, lacking appro-
priate epidermal cannabinoid signaling, displayed exacerbated allergic
skin inflammation, most probably because of the elevated MCP-2/
CCL8 chemokine production of the epidermal keratinocytes. On the
other hand, FAAH−/−mice (having higher eCB tone due to the impaired
AEA degradation) exhibited less severe symptoms, and inflammationculty ofMedicine, University of
. This is an open access article underwas also alleviated by cannabinoid receptor agonists in WT animals
cutaneous immune processes, and the “c(ut)annabinoid” system is
now proven to be one of their master regulators.
On the footsteps of Karsak et al., we further investigated the immuno-
logical role of the eCB-signaling using human epidermal keratinocytes.
We found that protein (but, interestingly, not mRNA) expression and ac-
tivity of the aforementioned eCB-degrading enzyme FAAHwas positively
regulated by Toll-like receptor (TLR) 2 activation (Oláh et al., 2016a). This
quite fascinating result clearly demonstrated how deeply the ECS is in-
volved in the regulation of one of themost fundamental immuneprocess-
es, i.e. the TLR-activation-induced pro-inflammatory signaling. Indeed,
administration of selective FAAH-inhibitors (and thereby restoration of
the homeostatic, anti-inflammatory eCB signaling leading to the activa-
tion of CB1 and CB2 receptors) was able to almost completely abrogate
the TLR2-mediated pro-inflammatory response (Oláh et al., 2016a).
Moreover, topically applied FAAH-inhibitors alleviated atopic dermatitis
(AD)-like symptoms ofNc/Tndmice (a.k.a. NC/Nga; amouse strain devel-
oping AD-like skin condition upon meeting certain dust mite antigens;
Yamada et al., 2016) too (Oláh et al., 2016a). Based on these data, FAAH
appears to be an important “decisionmaker” in the initiation andmainte-
nance of cutaneous inflammation; thus, increase/restoration of the ho-
meostatic cutaneous eCB tone by topically applied FAAH-inhibitors
possesses great potential in alleviating skin inflammation (Fig. 1A).
Another recently emerging, fascinating possibility to manage cuta-
neous inflammation through the cannabinoid signaling is the adminis-
tration of phytocannabinoids (pCB). Cannabis sativa contains over 100
different pCBs, the vastmajority of which have no psychotropic activity,
and usually possess a “favorable” side-effect profile, whichmakes these
substances particularly interesting drug candidates in treating several
inflammation-accompanied diseases (Maccarrone et al., 2015; Ligresti
et al., 2016). With respect to the skin, we have recently shown that
one of the best studied pCBs, (−)-cannabidiol (CBD), may have great
potential in managing acne, an inflammation-accompanied, extremely
prevalent cutaneous disease. Briefly, we found that without decreasingthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Classical and “non-classical” cannabinoid pathways in cutaneous inflammation. A) TLR2-activation increases FAAH expression and activity in human epidermal keratinocytes,
leading to the loss of homeostatic, anti-inflammatory eCB signaling and therefore results in elevated pro-inflammatory cytokine expression and release. Thus, FAAH-inhibitors can
selectively target the very first step of the cutaneous inflammatory processes by restoring the epidermal anti-inflammatory eCB-tone, and thereby normalizing the cytokine expression
and release of the keratinocytes (Oláh et al., 2016a). B) Schematic overview of the mechanism of CBD's complex anti-acne effects (Oláh et al., 2014). A2A: adenosine receptor 2A; AA:
arachidonic acid; AEA: anandamide; FAAH: fatty acid amide hydrolase; ERK1/2: extracellular signal-regulated kinase 1 and 2; MAPK: mitogen activated protein kinase; NF-κB: nuclear
factor kappa-light-chain enhancer of activated B cells; NRIP1: nuclear receptor interacting protein 1; TLR: Toll-like receptor; TRIB3: tribbles homolog 3; TRPV4: transient receptor
potential vanilloid 4.
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acne-mimicking, seborrheic lipid synthesis, decreased proliferation of
sebocytes, and exerted strong anti-inflammatory actions via “non-
classical” cannabinoid pathways (Fig. 1B). Indeed, sebostatic (lipid
lowering and anti-proliferative) actions were found to be coupled
to the activation of transient receptor potential vanilloid 4 (TRPV4)
ion channels followed by the subsequent inhibition of the ERK1/2
MAPK pathway and down-regulation of nuclear receptor interacting
protein 1 (NRIP1, a.k.a. RIP140). On the other hand, anti-inflammato-
ry effects were realized by the (most probably indirect) activation of
A2A adenosine receptors followed by up-regulation of tribbles homo-
log 3 (TRIB3) and inhibition of the pro-inflammatory p65 NF-κBpathway (Oláh et al., 2014). Moreover, although they exhibited im-
portant functional heterogeneity in influencing sebaceous lipogene-
sis, several other pCBs (namely (−)-cannabichromene [CBC], (−)-
cannabidivarin [CBDV], (−)-cannabigerol [CBG], (−)-
cannabigerovarin [CBGV] and (−)-Δ9-tetrahydrocannabidivarin
[THCV]) were proven to exert potent anti-inflammatory actions in
human sebocytes (Oláh et al., 2016b).
Collectively, in light of the above results, both increase/restoration of
the homeostatic cutaneous eCB-tone by FAAH-inhibitors and topical ad-
ministration of non-psychotropic pCBs hold out the promise to exert re-
markable anti-inflammatory actions, making them very exciting drug
candidates, deserving full clinical exploration as potent, yet safe
5A. Oláh, T. Bíró / EBioMedicine 16 (2017) 3–5(Maccarrone et al., 2015; Ligresti et al., 2016) novel class of anti-inflam-
matory agents.
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